FY25 Appendix 4E and Annual Report
| Stock | Genetic Signatures Ltd (GSS.ASX) |
|---|---|
| Release Time | 25 Aug 2025, 9:13 a.m. |
| Price Sensitive | Yes |
FY25 Appendix 4E and Annual Report
- Revenues up 62.8% to $15.9 million
- Loss up 12.6% to $20.1 million
- Successful transition to new CEO and Board members
- Streamlined product portfolio and operations
Genetic Signatures Limited has reported its FY25 results, marked by a 62.8% increase in revenues to $15.9 million but a 12.6% rise in loss to $20.1 million. The year saw significant changes at the Board and leadership levels, with Caroline Waldron assuming the role of Chair and Allison Rossiter appointed as the new CEO in September 2024. Under Rossiter's guidance, the company undertook a thorough review of its organizational structure, R&D initiatives, and product portfolio, resulting in a sharpened focus on core products and growth opportunities. Key decisions included discontinuing the development of an in-house automated instrument and instead partnering with Tecan Group and Repado to deliver a scalable, integrated sample-to-answer solution for syndromic testing laboratories. Genetic Signatures also streamlined its product portfolio, directing resources towards disease areas with the greatest customer value and patient impact. While the commercial momentum for the EasyScreen Gastrointestinal Parasite Detection Kit in the U.S. market has taken longer than anticipated, the company has responded by reorganizing resources and refining its go-to-market strategy. The company's EasyScreen respiratory tests have continued to deliver strong revenues in Australia, driven by ongoing COVID-19, influenza, and RSV infections. Looking ahead, Genetic Signatures is confident in its ability to achieve greater commercial success across all markets, driven by the development of the new automated platform and a focus on improving current workflows to enhance the customer experience.
The company reported a 62.8% increase in revenues to $15.9 million for the financial year ended 30 June 2025.
Genetic Signatures is confident in its ability to achieve greater commercial success across all markets, driven by the development of the new automated platform and a focus on improving current workflows to enhance the customer experience.